Vivek Daniel Paul is the Head of Molecular Biology at GangaGen. GangaGen is developing bacteriophage lysins and bacteriocins as novel non-traditional antibacterials to treat serious infections.
Vivek has over 20 years of experience in discovery and development of antibacterials to tackle AMR. His areas of expertise are molecular genetics and protein engineering. Vivek was instrumental in developing engineered Bacteriophages, Lysins and Bacteriocins platform at GangaGen and has several international patents to his credit.
Vivek is leading a CARB-X funded project to develop antibacterial proteins called klebicins as narrow-spectrum agents targeting multidrug-resistant K. pneumoniae, including the carbapenem-resistant and ESBL-expressing K. pneumoniae.